TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Day One Biopharmaceuticals ( (DAWN) ) is now available.
On November 24, 2025, Day One Biopharmaceuticals announced three-year results from its OJEMDA™ (tovorafenib) pivotal Phase 2 FIREFLY-1 trial, presented at the Society for Neuro-Oncology Annual Meeting. The updated data showed that 58% of patients completed 26 or more cycles of treatment, with a 53% overall response rate and a median duration of response of 19.4 months. The trial demonstrated that patients could maintain disease control during extended periods off therapy, with minimal tumor rebound and the option to reinitiate treatment if needed. These findings highlight tovorafenib’s potential as a second-line standard of care for pediatric low-grade glioma, offering patients meaningful time away from treatment.
The most recent analyst rating on (DAWN) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Day One Biopharmaceuticals stock, see the DAWN Stock Forecast page.
Spark’s Take on DAWN Stock
According to Spark, TipRanks’ AI Analyst, DAWN is a Neutral.
Day One Biopharmaceuticals shows strong growth potential, particularly with the success of OJEMDA and a solid cash position. However, consistent net losses, negative technical indicators, and a challenging valuation due to ongoing losses present significant risks. The strong momentum from recent earnings highlights provides some optimism, balancing out the weaker financial and technical aspects.
To see Spark’s full report on DAWN stock, click here.
More about Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biopharmaceutical company focused on developing and commercializing targeted therapies for individuals of all ages with life-threatening diseases. The company is particularly involved in creating treatments for pediatric low-grade glioma (pLGG), a common brain tumor in children, and has developed tovorafenib, a Type II RAF kinase inhibitor approved for treating patients with relapsed or refractory pLGG harboring BRAF alterations.
Average Trading Volume: 1,829,575
Technical Sentiment Signal: Hold
Current Market Cap: $874.8M
For a thorough assessment of DAWN stock, go to TipRanks’ Stock Analysis page.